Abstract
The low incidence, nonspecific clinical picture and absence of pathognomonic symptoms of vulvar adenocarcinoma make primary diagnosis very difficult. It could take months from the appearance of first symptoms to the final diagnosis and the start of specific treatment.There are limited options of standard treatment for this pathology. Therefore, attempts to use therapy that has proven itself in the other malignant tumors, based on molecular biological characteristics, are promising.Overexpression of HER2, which plays an important role in the carcinogenesis processes, is often observed in cases of extramammary Paget’s disease. We report a case of extramammary Paget’s vulvar cancer treated with a combination of cytostatic and targeted anti-HER2 agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have